Compare Marqeta Inc (MQ) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marqeta Inc vs Nuwellis Inc — how do they compare? Marqeta Inc trades at $17.1 (market cap $1.82B), while Nuwellis Inc trades at $0.69 (market cap $2.20M). The key difference: Marqeta Inc is far larger — about 827.3× Nuwellis Inc's market cap, and Marqeta Inc is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Marqeta Inc for 44 Days and Nuwellis Inc for 26 Days on average.
| MQ | NUWE | |
|---|---|---|
Market Cap | $1.82B | $2.20M |
Volume | 1,126,466 | 121,544 |
Sector | Technology | Health |
52-Week High | $20.32 | $146.65 |
52-Week Low | $15.04 | $0.68 |
Typical Hold Time | 44 Days | 26 Days |
Enterprise Value | $1.13B | -$1.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marqeta (MQ) trades at $17.06, up 3.08% with a bullish technical signal from moving averages. The company shows improving fundamentals with three consecutive quarterly EPS beats and revenue growth from $507M in 2024 to projected $677M in 2026. Recent partnerships with BVNK for stablecoin cards and Google for wallet expansion highlight strategic growth initiatives. However, valuation metrics remain elevated with a P/E of 189.56 and EV/EBITDA of 52.44 despite modest profitability margins.
MQ presents a mixed outlook with strong operational momentum but premium valuation. The stock offers growth potential through expanding payment partnerships and enterprise adoption, though faces risks from contract renewals in Q3 2026 and competitive pressure. Analyst consensus of $11.38 suggests caution despite recent bullish earnings revisions and institutional interest in the digital payments space.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
